Sitemap Contact Privacy Statement Imprint

Curriculum Vitae Anna Reustle, PhD

Affiliation
Scientist at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart
phone: ++49-711-8101 5013
fax: ++49-711-859295
email: anna.reustle@ikp-stuttgart.de
Dr. Anna Reustle

phone: ++49-711-81015013

Education and Professional Career
2008-2014 Studies of Molecular Biotechnology at the Ruprecht-Karls University Heidelberg, Heidelberg, Germany
2011 Bachelor thesis at the Department of Infectiology, Molecular Virology, University Hospital Heidelberg
2013-2014 Master thesis at the Department of Infectiology, Molecular Virology, University Hospital Heidelberg
2014-2018 PhD Thesis at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (Prof. Dr. M. Schwab); „Elucidation of underlying genomic, epigenomic and metabolomic factors contributing to the expression of candidate targets identified by HLA ligandome analysis in clear cell renal cell carcinoma“
Since 2018 Training as Clinical Chemist at the Robert-Bosch-Hospital
Since 2018 Scientist at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Selected References
  • Reustle A.; Di Marco M.; Meyerhoff C.; Nelde A.; Walz J.S.; Winter S.; Kandabarau, S.; Büttner, F.; Haag, M.; Backert, L.; Kowalewski, D.; Rausch, S.; Hennenlotter, J.; Stühler, V.; Scharpf, M.; Fend, F.; Stenzl, A.; Rammensee, H.G.; Bedke, J.; Stevanović, S.; Schwab, M.; Schaeffeler, E. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med 2020, 12(394). doi:10.1186/s13073-020-00731-8
  • Reustle, A.; Fisel, P.; Renner, O.; Büttner, F.; Winter, S.; Rausch, S.; Kruck, S.; Nies, A.T.; Hennenlotter, J.; Scharpf, M.; Fend, F.; Stenzl, A.; Bedke, J.; Schwab, M.; Schaeffeler, E. Characterization of the Breast Cancer Resistance Protein (BCRP/ABCG2) in clear cell renal cell carcinoma. Int J Cancer 2018 143(12), 3181-3193, doi: 10.1002/ijc.31741.
  • Schaeffeler, E.; Büttner, F.; Reustle, A.; Klumpp, V.; Winter, S.; Rausch, S.; Fisel, P.; Hennenlotter, J.; Kruck, S.; Stenzl, A.; Warheit, J.; Sonntag, D.; Scharpf, M.; Fend, F.; Agaimy, A.; Hartmann, A.; Bedke, J.; Schwab, M. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. Eur Urol Focus 2019, 5, 608–18. doi:10.1016/j.euf.2018.01.016
  • Büttner, F.; Winter, S.; Rausch, S.; Reustle, A.; Kruck, S.; Junker, K.; Stenzl, A.; Agaimy, A.; Hartmann, A.; Bedke, J.; Schwab, M.; Schaeffeler, E. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. Eur Urol 2015, 68(6), 1016–1020, doi: 10.1016/j.eururo.2015.05.045
Major Projects
  • Immunologic aspects of renal cell carcinoma
  • Omics analyses of clear cell renal cell carcinoma